Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Graciela M. Nogueras‐González et al.|Cancer Discovery|2018Cited by 570
The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Naval Daver, Sreyashi Basu et al.|Cancer|2018Cited by 339
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trialAhmed O. Kaseb, Padmanee Sharma, Elshad Hasanov et al.|The Lancet. Gastroenterology & hepatology|2022Cited by 255
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analysesAlexander Ling, Patrick Y. Wen, Jennifer Gantchev et al.|Science Translational Medicine|2025Cited by 12
Investigative needle core biopsies for multi-omics in GlioblastomaKenny K.H. Yu, Nathalie Y.R. Agar, Sreyashi Basu et al.|medRxiv|2023Cited by 6